Skip to content
2000
image of Regulatory Prospects for Stem Cell in Clinical Trials: UAE, US, and India

Abstract

Introduction

Stem cell therapies are advancing rapidly, requiring robust regulations to ensure safety and ethics. The UAE, with authorities like MOHAP, DOH, DHA, and DHCR, is actively involved in clinical research but faces regulatory inconsistencies across emirates. In contrast, the U.S. (FDA, NIH) and India (CDSCO, ICMR) have unified national frameworks with specific stem cell guidelines. This study compares the UAE’s system with those of the U.S. and India to identify strengths and gaps.

Methods

A comparative literature review was conducted using regulatory documents, clinical trial registries, peer-reviewed studies, and interviews. The focus was on analyzing the regulatory frameworks in the UAE, the U.S., and India, especially regarding stem cell clinical research.

Results

The UAE has established ethical review boards and oversight mechanisms but lacks unified national guidelines and consistent application across emirates. In comparison, the U.S. and India have more cohesive, transparent, and accessible regulatory systems for stem cell research.

Discussion

The UAE’s efforts in promoting stem cell research are notable, but fragmentation among regulatory authorities hampers coordination. Adopting centralized policies, like in the U.S. and India, could improve efficiency, transparency, and compliance. A national registry and stem cell-specific guidelines are also needed.

Conclusion

The UAE has made commendable progress in regulating stem cell clinical research. However, the absence of unified national guidelines and inter-emirate coordination remains a challenge. Learning from the centralized frameworks of the U.S. and India can help bridge these gaps. Strengthening oversight will enhance patient safety, ethical compliance, and global collaboration.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cscr/10.2174/011574888X372893250804112424
2025-08-13
2025-12-31

  • From This Site

    /content/journals/cscr/10.2174/011574888X372893250804112424
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Health regulatory authorities | The Official Portal of the UAE Government. Available from:https://u.ae/en/information-and-services/health-and-fitness/health-authorities 2025
  2. Castillo-Aleman Y.M. Ventura-Carmenate Y. Rivero-Jimenez R.A. Bencomo-Hernandez A.A. Regulatory prospects of clinical trials with stem cells in the United Arab Emirates. Int J Stem Cell Res Ther 2021 8 1 10.23937/2469‑570X/1410073
    [Google Scholar]
  3. Available from:http://apps.who.int/bookorders 2018
  4. Home, ClinicalTrials.gov. Available from:https://clinicaltrials.gov/ 2025
  5. Primary registries. Available from:https://www.who.int/tools/clinical-trials-registry-platform/network/primary-registries 2025
  6. Home, Ministry of Health and Prevention - UAE. Available from:https://mohap.gov.ae/en/home 2025
  7. Research and Innovation Center. Available from:https://www.doh.gov.ae/en/research/landing-page 2025
  8. Health research bank, Ministry of Health and Prevention - UAE. Available from:https://mohap.gov.ae/en/open-data/health-research-bank
  9. George B. Regulations and guidelines governing stem cell based products: Clinical considerations. Perspect Clin Res 2011 2 3 94 99 10.4103/2229‑3485.83228 21897884
    [Google Scholar]
  10. eCFR:: 21 CFR Part 1271 -- Human Cells, tissues, and cellular and tissue-based products. Available from:https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271 2025
  11. Liras A. Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects. J Transl Med 2010 8 1 131 10.1186/1479‑5876‑8‑131 21143967
    [Google Scholar]
  12. Bieback K. Kinzebach S. Karagianni M. Translating research into clinical scale manufacturing of mesenchymal stromal cells. 2010 2010 193519 10.4061/2010/193519
    [Google Scholar]
  13. Gee A. Mesenchymal stem-cell therapy in a regulated environment. Cytotherapy 2001 3 5 397 398 10.1080/146532401753277391 11953020
    [Google Scholar]
  14. Hyun I. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges. J Law Med Ethics 2010 38 2 277 285 10.1111/j.1748‑720X.2010.00488.x 20579251
    [Google Scholar]
  15. Kim J.Y. Nam Y. Rim Y.A. Ju J.H. Review of the current trends in clinical trials involving induced pluripotent stem cells. Stem Cell Rev Rep 2022 18 1 142 154 10.1007/s12015‑021‑10262‑3 34532844
    [Google Scholar]
  16. Zuk P.A. Zhu M. Ashjian P. De Ugarte D.A. Huang J.I. Mizuno H. Alfonso Z.C. Fraser J.K. Benhaim P. Hedrick M.H. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002 13 12 4279 4295 10.1091/mbc.e02‑02‑0105 12475952
    [Google Scholar]
  17. Holden C. Versatile cells against intractable diseases. Science 2002 297 5581 500 502 10.1126/science.297.5581.500
    [Google Scholar]
  18. Submission of clinical trial application for evaluating safety and efficacy • requirements for permission of new drugs approval • preparation of the quality information for drug submission for new drug approval: Biotechnological/biological products guidance for industry. 2002
    [Google Scholar]
  19. Clinical Trials Registry - India (CTRI). Available from:https://ctri.nic.in/Clinicaltrials/login.php 2025
  20. Sonak H.Y. Rose W. A nationwide representative analysis of pediatric COVID-19 from a National Clinical Registry in India. Indian J Pediatr 2023 90 10 965 966 10.1007/s12098‑023‑04816‑1 37592103
    [Google Scholar]
  21. Stem cells and cell based products. Available from:https://www.cdsco.gov.in/opencms/opencms/en/biologicals/Stem-cells-and-Cell-based-Products/ 2021
  22. Isasi R. Ginoza M. Jongsma K. Assen L. Fabbri M. Mending the gaps: Ethically sensitive cells and the evolution of European stem cell policy. Regen Med 2022 17 8 581 595 10.2217/rme‑2022‑0043 35670098
    [Google Scholar]
  23. Ferrero I. Piccinini F. Marrazzo P. Monti M. Pipino C. Banche Niclot A.S.G. Proto C.F. Ragni E. Hass R. Stella G.M. Berni P. Ivanovska A. Mareschi K. State of the art and new trends from the second international stemnet meeting. Int J Mol Sci 2024 25 4 2221 https://www.mdpi.com/1422-0067/25/4/2221/htm 10.3390/ijms25042221 38396899
    [Google Scholar]
  24. Matthews K.R.W. Lowe S.J. Master Z. US state laws on medical freedom and investigational stem cell procedures: A call to focus on state-based legislation. Cytotherapy 2024 26 4 404 409 10.1016/j.jcyt.2024.01.002 38310500
    [Google Scholar]
  25. Park S.J. Kim Y.Y. Han J.Y. Kim S.W. Kim H. Ku S.Y. Advancements in human embryonic stem cell research: Clinical applications and ethical issues. Tissue Eng Regen Med 2024 21 3 379 394 10.1007/s13770‑024‑00627‑3 38502279
    [Google Scholar]
  26. Kuchakzadeh F. Ai J. Ebrahimi-Barough S. Tissue engineering and stem cell-based therapeutic strategies for premature ovarian insufficiency. Regen Ther 2024 25 10 23 10.1016/j.reth.2023.11.007 38108045
    [Google Scholar]
  27. What are 351(A) & 351(K)? Available from:https://www.freyrsolutions.com/what-are-351a-351k 2022
  28. Fda, cder, terriecrescenzi. clinical pharmacology data to support a demonstration of biosimilarity to a reference product: Guidance for industry. Available from:http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmand/orhttp://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 2016
  29. Biosimilars hot topic: Extrapolation of indications. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ 2018
  30. Liu Y. Wang Y. Wang M. Zhai S. Hou C. Sun F. Jian L. Evaluating biosimilars: Safety, efficacy, and regulatory considerations in clinical studies. Int J Clin Pharm 2025 47 1 232 236 10.1007/s11096‑024‑01825‑8 39527168
    [Google Scholar]
  31. Considerations in demonstrating interchangeability with a reference product guidance for Industry. Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry 2025
  32. Aboul-Soud M.A.M. Alzahrani A.J. Mahmoud A. Induced pluripotent stem cells (Ipscs)—roles in regenerative therapies, disease modelling and drug screening. Cells 2021 10 9 2319 10.3390/cells10092319 34571968
    [Google Scholar]
  33. Scopus preview - Scopus - Welcome to Scopus. Available from:https://www.scopus.com/standard/marketing.uri 2025
  34. Bian N. Chu C. Rung S. Huangphattarakul V. Man Y. Lin J. Hu C. Immunomodulatory biomaterials and emerging analytical techniques for probing the immune micro-environment. Tissue Eng Regen Med 2023 20 1 11 24 10.1007/s13770‑022‑00491‑z 36241939
    [Google Scholar]
  35. Yadav S. Khan J. Yadav A. Applications of scaffolds in tissue engineering: Current utilization and future prospective. Curr Gene Ther 2024 24 2 94 109 10.2174/0115665232262167231012102837 37921144
    [Google Scholar]
  36. Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products. Available from:www.ema.europa.eu/contact 2014
/content/journals/cscr/10.2174/011574888X372893250804112424
Loading
Regulatory Prospects for Stem Cell in Clinical Trials: UAE, US, and India
Bentham Science Publishers ; https://doi.org/10.2174/011574888X372893250804112424
/content/journals/cscr/10.2174/011574888X372893250804112424
/content/journals/cscr/10.2174/011574888X372893250804112424
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: regulatory framework ; good clinical practice (GCP) ; research ethics ; stem cell therapy ; Clinical research

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test